Literature DB >> 12586590

Overexpression of the c-Met/HGF receptor and its prognostic significance in uterine cervix carcinomas.

Cem Baykal1, Ayşe Ayhan, Atakan Al, Kunter Yüce, Ali Ayhan.   

Abstract

OBJECTIVE: The purpose of this study is to evaluate the significance of the c-Met/hepatocyte growth factor receptor expression in invasive cervical carcinoma.
METHODS: Ninety-Four patients with FIGO stage 1B disease, treated primarily with surgery, were studied immunohistochemically. Of the cases, 67 were squamous carcinoma and 27 were nonsquamous (10 were adenocarcinoma, 15 were adenosquamous carcinoma, and 2 were indifferentiated carcinoma). Immunohistochemically stained c-Met slides of primary malignancies were evaluated blindly of clinical outcome and other histopathological factors.
RESULTS: Overexpression of c-Met was found in 56 of 94 specimens. Primary tumors which show recurrences were found to be c-Met overexpressors. Univariate survival analysis (Kaplan-Meier) showed that c-Met overexpression is significantly correlated with disease-free survival. Moreover the diameter of the primary tumor, deep cervical stromal invasion, presence of metastatic lymph node, number of metastatic lymph nodes and c-Met overexpression were significantly correlated with overall 5-year survival. Furthermore multivariant analysis with Cox regression showed that the presence of metastatic lymph node and immunopositivity for c-Met are significantly correlated with overall survival, while c-Met overexpression was found to be an independent variable for disease-free survival.
CONCLUSION: These results reveal that c-Met oncogene overexpression is an important parameter for disease progression, recurrence, and survival in early-stage invasive uterine cervix carcinomas.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12586590     DOI: 10.1016/s0090-8258(02)00073-2

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  21 in total

1.  In vitro and in vivo potentiating the cytotoxic effect of radiation on human U251 gliomas by the c-Met antisense oligodeoxynucleotides.

Authors:  Sheng-hua Chu; Zhi-an Zhu; Xian-hou Yuan; Zhi-qiang Li; Pu-cha Jiang
Journal:  J Neurooncol       Date:  2006-04-29       Impact factor: 4.130

Review 2.  The Interaction Between Human Papillomaviruses and the Stromal Microenvironment.

Authors:  B Woodby; M Scott; J Bodily
Journal:  Prog Mol Biol Transl Sci       Date:  2016-10-11       Impact factor: 3.622

3.  c-Met Overexpression in Cervical Cancer, a Prognostic Factor and a Potential Molecular Therapeutic Target.

Authors:  Tamer Refaat; Eric D Donnelly; Sean Sachdev; Vamsi Parimi; Samar El Achy; Prarthana Dalal; Mohamed Farouk; Natasha Berg; Irene Helenowski; Jeffrey P Gross; John Lurain; Jonathan B Strauss; Gayle Woloschak; Jian-Jun Wei; William Small
Journal:  Am J Clin Oncol       Date:  2017-12       Impact factor: 2.339

4.  Exposure-Response and Tumor Growth Inhibition Analyses of the Monovalent Anti-c-MET Antibody Onartuzumab (MetMAb) in the Second- and Third-Line Non-Small Cell Lung Cancer.

Authors:  Kelong Han; Pascal Chanu; Fredrik Jonsson; Helen Winter; René Bruno; Jin Jin; Mark Stroh
Journal:  AAPS J       Date:  2016-12-27       Impact factor: 4.009

Review 5.  The tumor microenvironment and metastatic disease.

Authors:  Sarah Jane Lunt; Naz Chaudary; Richard P Hill
Journal:  Clin Exp Metastasis       Date:  2008-06-10       Impact factor: 5.150

6.  Human papillomavirus type 16 E5-mediated upregulation of Met in human keratinocytes.

Authors:  Matthew L Scott; David T Coleman; Kinsey C Kelly; Jennifer L Carroll; Brittany Woodby; William K Songock; James A Cardelli; Jason M Bodily
Journal:  Virology       Date:  2018-03-31       Impact factor: 3.616

Review 7.  MET: a promising anticancer therapeutic target.

Authors:  Solange Peters; Alex A Adjei
Journal:  Nat Rev Clin Oncol       Date:  2012-05-08       Impact factor: 66.675

8.  A novel multipurpose monoclonal antibody for evaluating human c-Met expression in preclinical and clinical settings.

Authors:  Beatrice S Knudsen; Ping Zhao; James Resau; Sandra Cottingham; Ermanno Gherardi; Eric Xu; Bree Berghuis; Jennifer Daugherty; Tessa Grabinski; Jose Toro; Troy Giambernardi; R Scot Skinner; Milton Gross; Eric Hudson; Eric Kort; Ernst Lengyel; Aviva Ventura; Richard A West; Qian Xie; Rick Hay; George Vande Woude; Brian Cao
Journal:  Appl Immunohistochem Mol Morphol       Date:  2009-01

Review 9.  Cancer therapy using tumor-associated antigens to reduce side effects.

Authors:  David Siu
Journal:  Clin Exp Med       Date:  2009-05-01       Impact factor: 5.057

10.  Chromosomal imbalances in four new uterine cervix carcinoma derived cell lines.

Authors:  Alfredo Hidalgo; Alberto Monroy; Rosa Ma Arana; Lucía Taja; Guelaguetza Vázquez; Mauricio Salcedo
Journal:  BMC Cancer       Date:  2003-03-20       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.